The University of Chicago Header Logo

Connection

George Perry to Amyloid beta-Peptides

Back to Details
This is a "connection" page, showing publications George Perry has written about Amyloid beta-Peptides.
George Perry
Connection Strength
5.320
Amyloid beta-Peptides
  1. Status and future directions of clinical trials in Alzheimer's disease. Int Rev Neurobiol. 2020; 154:3-50.
    View in: PubMed
    Score: 0.576
  2. The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. Lab Invest. 2019 07; 99(7):958-970.
    View in: PubMed
    Score: 0.522
  3. Expression Profiling of Cytokine, Cholinergic Markers, and Amyloid-ß Deposition in the APPSWE/PS1dE9 Mouse Model of Alzheimer's Disease Pathology. J Alzheimers Dis. 2018; 62(1):467-476.
    View in: PubMed
    Score: 0.483
  4. Thermodynamics of Amyloid-ß Fibril Elongation: Atomistic Details of the Transition State. ACS Chem Neurosci. 2018 04 18; 9(4):783-789.
    View in: PubMed
    Score: 0.482
  5. Elongation affinity, activation barrier, and stability of Aß42 oligomers/fibrils in physiological saline. Biochem Biophys Res Commun. 2017 05 27; 487(2):444-449.
    View in: PubMed
    Score: 0.460
  6. Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting Aß by Using Several Synthetic and Herbal Compounds. Oxid Med Cell Longev. 2016; 2016:7361613.
    View in: PubMed
    Score: 0.420
  7. The Amyloid Cascade Hypothesis: A Conclusion in Search of Support. Am J Pathol. 2025 Nov; 195(11):1988-1997.
    View in: PubMed
    Score: 0.194
  8. Meta-Analysis in Transgenic Alzheimer's Disease Mouse Models Reveals Opposite Brain Network Effects of Amyloid-ß and Phosphorylated Tau Proteins. J Alzheimers Dis. 2024; 99(2):595-607.
    View in: PubMed
    Score: 0.183
  9. Lessons from antiamyloid-ß immunotherapies in Alzheimer's disease. Handb Clin Neurol. 2023; 193:267-292.
    View in: PubMed
    Score: 0.171
  10. Playing Russian Roulette with Alzheimer's Disease Patients: Do the Cognitive Benefits of Lecanemab Outweigh the Risk of Edema, Stroke and Encephalitis? J Alzheimers Dis. 2023; 92(3):799-801.
    View in: PubMed
    Score: 0.171
  11. Beta-amyloid 1-42 monomers, but not oligomers, produce PHF-like conformation of Tau protein. Aging Cell. 2016 10; 15(5):914-23.
    View in: PubMed
    Score: 0.109
  12. Laser-Induced In-Source Decay Applied to the Determination of Amyloid-Beta in Alzheimer's Brains. ACS Chem Neurosci. 2016 Mar 16; 7(3):261-8.
    View in: PubMed
    Score: 0.105
  13. Accumulation of intraneuronal amyloid-ß is common in normal brain. Curr Alzheimer Res. 2014 May; 11(4):317-24.
    View in: PubMed
    Score: 0.094
  14. The structures of the E22? mutant-type amyloid-ß alloforms and the impact of E22? mutation on the structures of the wild-type amyloid-ß alloforms. ACS Chem Neurosci. 2013 Feb 20; 4(2):310-20.
    View in: PubMed
    Score: 0.085
  15. Structures and free energy landscapes of aqueous zinc(II)-bound amyloid-ß(1-40) and zinc(II)-bound amyloid-ß(1-42) with dynamics. J Biol Inorg Chem. 2012 Aug; 17(6):927-38.
    View in: PubMed
    Score: 0.082
  16. Amyloid-ß peptide structure in aqueous solution varies with fragment size. J Chem Phys. 2011 Nov 28; 135(20):205101.
    View in: PubMed
    Score: 0.079
  17. Molecular pathogenesis of Alzheimer's disease: reductionist versus expansionist approaches. Int J Mol Sci. 2009 Mar; 10(3):1386-1406.
    View in: PubMed
    Score: 0.066
  18. Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis. 2009; 18(2):447-52.
    View in: PubMed
    Score: 0.065
  19. Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol. 2008 Jun; 67(6):523-31.
    View in: PubMed
    Score: 0.062
  20. Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther. 2007 Jun; 321(3):823-9.
    View in: PubMed
    Score: 0.056
  21. Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau. Am J Alzheimers Dis Other Demen. 2006 Mar-Apr; 21(2):126-30.
    View in: PubMed
    Score: 0.053
  22. Redox metals and oxidative abnormalities in human prion diseases. Acta Neuropathol. 2005 Sep; 110(3):232-8.
    View in: PubMed
    Score: 0.051
  23. Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective? Int J Exp Pathol. 2005 Jun; 86(3):133-8.
    View in: PubMed
    Score: 0.050
  24. Microglial modulation as a therapeutic strategy in Alzheimer's disease: Focus on microglial preconditioning approaches. J Cell Mol Med. 2024 Aug; 28(15):e18554.
    View in: PubMed
    Score: 0.048
  25. Label-Free In Situ Chemical Characterization of Amyloid Plaques in Human Brain Tissues. ACS Chem Neurosci. 2024 04 03; 15(7):1469-1483.
    View in: PubMed
    Score: 0.046
  26. Revision of Alzheimer's diagnostic criteria or relocation of the Potemkin village. Ageing Res Rev. 2024 01; 93:102173.
    View in: PubMed
    Score: 0.046
  27. Evaluation of N- and O-Linked Indole Triazines for a Dual Effect on a-Synuclein and Tau Aggregation. ACS Chem Neurosci. 2023 11 01; 14(21):3913-3927.
    View in: PubMed
    Score: 0.045
  28. Passive Alzheimer's immunotherapy: A promising or uncertain option? Ageing Res Rev. 2023 09; 90:101996.
    View in: PubMed
    Score: 0.044
  29. The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes. J Alzheimers Dis. 2023; 94(2):497-507.
    View in: PubMed
    Score: 0.043
  30. Association of COVID-19 with Risk and Progression of Alzheimer's Disease: Non-Overlapping Two-Sample Mendelian Randomization Analysis of 2.6 Million Subjects. J Alzheimers Dis. 2023; 96(4):1711-1720.
    View in: PubMed
    Score: 0.043
  31. Immune modulations and immunotherapies for Alzheimer's disease: a comprehensive review. Rev Neurosci. 2022 06 27; 33(4):365-381.
    View in: PubMed
    Score: 0.039
  32. The Amyloid-ß Pathway in Alzheimer's Disease. Mol Psychiatry. 2021 10; 26(10):5481-5503.
    View in: PubMed
    Score: 0.039
  33. Decreased salivary lactoferrin levels are specific to Alzheimer's disease. EBioMedicine. 2020 Jul; 57:102834.
    View in: PubMed
    Score: 0.036
  34. Precision pharmacology for Alzheimer's disease. Pharmacol Res. 2018 04; 130:331-365.
    View in: PubMed
    Score: 0.030
  35. Inhibition of mitochondrial fragmentation protects against Alzheimer's disease in rodent model. Hum Mol Genet. 2017 11 01; 26(21):4118-4131.
    View in: PubMed
    Score: 0.030
  36. Mitochondrial traffic jams in Alzheimer's disease - pinpointing the roadblocks. Biochim Biophys Acta. 2016 10; 1862(10):1909-17.
    View in: PubMed
    Score: 0.027
  37. Microbes and Alzheimer's Disease. J Alzheimers Dis. 2016; 51(4):979-84.
    View in: PubMed
    Score: 0.026
  38. Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis. Expert Rev Neurother. 2010 May; 10(5):683-91.
    View in: PubMed
    Score: 0.018
  39. Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem Int. 2009 Feb; 54(2):84-8.
    View in: PubMed
    Score: 0.016
  40. Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J Neurochem. 2008 Aug; 106(3):1350-6.
    View in: PubMed
    Score: 0.015
  41. Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother. 2008 Apr-May; 62(4):199-207.
    View in: PubMed
    Score: 0.015
  42. The role of novel chitin-like polysaccharides in Alzheimer disease. Neurotox Res. 2007 Dec; 12(4):269-74.
    View in: PubMed
    Score: 0.015
  43. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? Expert Rev Neurother. 2007 May; 7(5):473-85.
    View in: PubMed
    Score: 0.014
  44. Increased expression of p130 in Alzheimer disease. Neurochem Res. 2007 Apr-May; 32(4-5):639-44.
    View in: PubMed
    Score: 0.014
  45. Neuropathology in Alzheimer's disease: awaking from a hundred-year-old dream. Sci Aging Knowledge Environ. 2006 May 03; 2006(8):pe10.
    View in: PubMed
    Score: 0.013
  46. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol. 2006 Jun; 111(6):503-9.
    View in: PubMed
    Score: 0.013
  47. Chitin-like polysaccharides in Alzheimer's disease brains. Curr Alzheimer Res. 2005 Oct; 2(4):419-23.
    View in: PubMed
    Score: 0.013
  48. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res Rev. 2004 Jul; 3(3):319-26.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.